Kriya Therapeutics Inc. has presented preclinical data on their novel candidate, KT-A261, an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab, administered as a single intravitreal injection to improve ocular concentrations of adalimumab, for the potential treatment of noninfectious uveitis (NIU).